Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Lorenza Rimassa\textsuperscript{a,b} Robin Kate Kelley\textsuperscript{c} Tim Meyer\textsuperscript{d} Baek-Yeol Ryoo\textsuperscript{e} Philippe Merle\textsuperscript{f} Joong-Won Park\textsuperscript{g} Jean-Frederic Blanc\textsuperscript{h} Ho Yeong Lim\textsuperscript{i} Albert Tran\textsuperscript{j,k,l} Yi-Wah Chan\textsuperscript{m} Paul McAdam\textsuperscript{m} Evelyn Wang\textsuperscript{n} Ann-Lii Cheng\textsuperscript{o} Anthony B. El-Khoueiry\textsuperscript{p} Ghassan K. Abou-Alfa\textsuperscript{q,r}

\textsuperscript{a}Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy; \textsuperscript{b}Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy; \textsuperscript{c}UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; \textsuperscript{d}Royal Free Hospital and UCL Cancer Institute, London, UK; \textsuperscript{e}Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; \textsuperscript{f}Groupement Hospitalier Lyon Nord, Lyon, France; \textsuperscript{g}National Cancer Center, Goyang, Republic of Korea; \textsuperscript{h}Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France; \textsuperscript{i}Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; \textsuperscript{j}Université Côte d’Azur, Nice, France; \textsuperscript{k}CHU de Nice, Digestive Center, Nice, France; \textsuperscript{l}INSERM, U1065, C3M, Team 8, Nice, France; \textsuperscript{m}Fios Genomics Ltd, Edinburgh, UK; \textsuperscript{n}Exelixis, Inc., Alameda, CA, USA; \textsuperscript{o}National Taiwan University College of Medicine, Taipei, Taiwan; \textsuperscript{p}USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; \textsuperscript{q}Memorial Sloan Kettering Cancer Center, New York, NY, USA; \textsuperscript{r}Weill Medical College at Cornell University, New York, NY, USA

Keywords
Hepatocellular carcinoma · Plasma biomarkers · Prognostic factors · Cabozantinib

Abstract
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated according to plasma biomarker levels. Methods: Baseline plasma levels were evaluated for MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PIGF, IL-8, EPO, ANG2, IGF-1, VEGF-C, and c-KIT for 674/707 randomized patients; and Week 4 levels were evaluated for MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PIGF, IL-8, and EPO for 614 patients. OS and PFS were analyzed by baseline levels as dichotomized or continuous variables and by on-treatment changes at Week 4 as continuous variables; biomarkers were considered potentially prognostic if $p < 0.05$ and predictive if $p < 0.05$ for the interaction between treatment and the biomarker. Multivariable analyses adjusting for clinical covariates were also performed. Results: In the placebo group, high levels of MET, HGF, GAS6, IL-8, and ANG2 and low levels of IGF-1 were associated with shorter OS in univariate and multivariable analyses; these associations were also observed for MET, IL-8, and ANG2 in the cabozantinib group. Hazard ratios for OS and PFS favored cabozantinib over the placebo at low and high baseline levels for all biomarkers. No baseline biomarkers were A, PIGF, IL-8, and EPO for 614 patients. OS and PFS were analyzed by baseline levels as dichotomized or continuous variables and by on-treatment changes at Week 4 as continuous variables; biomarkers were considered potentially prognostic if $p < 0.05$ and predictive if $p < 0.05$ for the interaction between treatment and the biomarker. Multivariable analyses adjusting for clinical covariates were also performed. Results: In the placebo group, high levels of MET, HGF, GAS6, IL-8, and ANG2 and low levels of IGF-1 were associated with shorter OS in univariate and multivariable analyses; these associations were also observed for MET, IL-8, and ANG2 in the cabozantinib group. Hazard ratios for OS and PFS favored cabozantinib over the placebo at low and high baseline levels for all biomarkers. No baseline biomarkers were
predictive of a treatment benefit. Cabozantinib promoted pharmacodynamic changes in several biomarkers, including increases in VEGF-A, PI GF, AX L, and GAS6 levels and decreases in VEGFR2 and HGF levels; these changes were not associated with OS or PFS. **Conclusion:** Cabozantinib improved OS and PFS versus placebo at high and low baseline concentrations for all biomarkers analyzed. Low baseline levels of MET, HGF, GAS6, IL-8, and ANG2 and high levels of IGF-1 were identified as potential favorable prognostic biomarkers for survival in previously treated advanced HCC. Although cabozantinib promoted pharmacodynamic changes in several biomarkers, these changes were not associated with survival.

© 2021 The Author(s).
Published by S. Karger AG, Basel

**Introduction**

Hepatocellular carcinoma (HCC) is a clinically and molecularly heterogeneous disease, and this diversity has impeded the identification of prognostic plasma biomarkers associated with the clinical outcome and predictive plasma biomarkers associated with a treatment benefit for specific therapies. Alpha-fetoprotein (AFP), the most thoroughly characterized protein in this context, has been associated with the prognosis of HCC, with low serum AFP levels associated with improved survival across stages of the disease [1, 2]. Previous studies have identified other plasma biomarkers as potential prognostic factors in advanced HCC, including proteins related to angiogenesis and/or receptor tyrosine kinase signaling such as VEGF-A, ANG2, HGF, MET, IGF-1, and IGF-2 and proteins related to inflammation such as IL-6 and IL-8 [3–6]. Predictive biomarkers associated with response to a specific therapy have not been defined to date in HCC. Recently, a broad survey of plasma proteins identified several potentially predictive biomarkers for a survival benefit with the multigated receptor tyrosine kinase inhibitor (TKI) regorafenib versus placebo [6]. In addition, studies have shown a differential treatment benefit for the anti-VEGFR2 antibody ramucirumab compared with the placebo based on serum levels of AFP [7].

Cabozantinib inhibits receptor tyrosine kinases implicated in HCC progression, tumor immunosuppression, and resistance to antiangiogenic therapy, including VEGF receptors 1–3, MET, and the TAM family kinases TYRO3, AX L, and MER [8]. In the pivotal phase 3 CELESTIAL trial, cabozantinib significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with advanced HCC previously treated with sorafenib and up to 2 prior systemic regimens. The median OS was 10.2 months for cabozantinib versus 8.0 months for the placebo (hazard ratio [HR] 0.76, 95% confidence interval 0.63–0.92; \(p = 0.005\)), and the median PFS was 5.2 months versus 1.9 months (HR 0.44, 95% confidence interval 0.36–0.52; \(p < 0.001\)) [9].

Here, we present an exploratory analysis of OS and PFS in CELESTIAL based on plasma biomarker levels at baseline and on-treatment changes at Week 4. Biomarkers chosen for the study included cabozantinib targets (MET, AX L, VEGFR2, and c-KIT) and their ligands (HGF, GAS6, VEGF-A, PI GF, and VEGF-C) and other plasma proteins with reported prognostic significance in HCC (IL-8, EPO, ANG2, and IGF-1) [4]. Outcomes based on AFP levels in CELESTIAL have been previously reported [10] and were not included in the current analysis.

**Materials and Methods**

**Study Design and Patients**

The study design and methods for the global, randomized, placebo-controlled phase 3 CELESTIAL trial (NCT01908426) have been previously reported [9]. Eligible patients had HCC that was not amenable to curative treatment, Child-Pugh A liver function, and Eastern Cooperative Oncology Group performance status of 0 or 1. Patients must have received prior sorafenib and could have received up to 2 prior systemic regimens for HCC, with disease progression on at least one prior regimen.

Patients were randomized 2:1 to receive cabozantinib (60 mg orally, once daily) or a matched placebo. Randomization was stratified by disease etiology: geographic region; and the presence of extrahepatic spread, macrovascular invasion, or both. Patients continued to receive study treatment as long as they experienced clinical benefit as judged by the investigator or until they experienced unacceptable toxicity. Treatment interruptions and dose reductions (to 40 mg and then to 20 mg) were used to manage adverse events.

The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The Ethics Committee or institutional review board at each center approved the protocol, and all patients provided written informed consent.

**Endpoints and Assessments**

The primary endpoint was OS, and secondary endpoints were PFS and the objective response rate. The clinical outcome according to plasma biomarker levels was an exploratory endpoint.

Tumor response and progression were assessed every 8 weeks by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 [11]. The data cutoff date was June 1, 2017.

Plasma samples were collected at baseline and on treatment at Week 4 (Week 5, Day 1). Samples were analyzed for soluble biomarker levels by the Luminex assay (Assay Gate, Ijamsville, MD, USA). Baseline biomarker levels were determined for 13 proteins (MET, AX L, VEGFR2, HGF, GAS6, VEGF-A, PI GF, IL-8, EPO,
ANG2, IGFl-1, VEGF-C, and c-KIT), and Week 4 biomarker levels were determined for 9 proteins (MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PIGF, IL-8, and EPO) due to limited availability of plasma samples.

**Statistical Analysis**

Efficacy and safety outcomes for CELESTIAL have been previously reported [9]. The exploratory biomarker analyses reported here were not powered for statistical significance and are considered hypothesis-generating. Analyses were performed with SAS version 9.4 or R software version 3.5 or later.

On-treatment changes in biomarker levels were expressed as fold change at Week 4 from baseline using paired measurements for each patient. Fold changes were compared within each treatment group and between treatment groups using linear modeling.

For survival analyses, differences were tested using log-rank statistics, median durations were estimated by the Kaplan-Meier method, and HRs were estimated using Cox regression models. Where indicated, multivariable models were used, adjusting for macrovascular invasion (no or yes), extrahepatic spread (no or yes), AFP level (<400 or ≥ 400 ng/mL), Eastern Cooperative Oncology Group performance status (0 or ≥ 1), and albumin-bilirubin grade (1 or ≥ 2) [12]; these clinical covariates and cutoffs were chosen based on a multivariable analysis of pooled phase 3 studies with sorafenib [13] and univariate analyses of CELESTIAL [14]. No adjustments were made for multiple comparisons.

OS and PFS were evaluated according to baseline biomarkers, with protein levels expressed either as discrete variables dichotomized at the median of the combined treatment groups or as continuous variables. For subgroup analyses comparing cabozantinib versus placebo, baseline biomarker levels dichotomized at the median were also used. To identify potential prognostic factors, outcomes were evaluated for high versus low biomarker levels within each treatment group, with biomarker levels expressed either as dichotomized variables or continuous variables, using the log2-transformed protein concentrations. Biomarkers were considered potentially prognostic if \( p < 0.05 \) in these analyses. The association of on-treatment changes in biomarker levels with OS and PFS was evaluated using continuous analyses of the log2-transformed fold change from baseline at Week 4. HR < 1 indicates that longer survival was associated with higher protein levels in the dichotomized or continuous baseline analyses and with increased protein levels at Week 4 compared with baseline in the on-treatment analyses; whereas, an HR > 1 favors lower protein levels at baseline or decreased levels at Week 4 for longer survival.

To identify potential predictive factors, the interaction between the biomarker and treatment was assessed using a Cox proportional hazards model with an interaction term. Biomarkers were considered potentially predictive if \( \beta_{\text{interaction}} < 0.05 \) for the interaction between treatment and the biomarker level.

**Results**

As of June 1, 2017, 707 patients were randomized 2:1 to receive cabozantinib or the placebo. Baseline characteristics were generally balanced between the treatment groups [9]. At baseline, plasma samples for biomarker analysis were available for 447/470 (95%) patients in the cabozantinib group and 227/237 (96%) patients in the placebo group. Plasma samples at both baseline and Week 4 were available for 399 (85%) patients in the cabozantinib group and 215 (91%) patients in the placebo group.

Baseline levels of 13 biomarkers (MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PIGF, IL-8, EPO, ANG2, IGFl-1, VEGF-C, and c-KIT) were tested for potential prognostic significance within each treatment group by comparing OS for high versus low dichotomized biomarkers using both univariate analyses and multivariable analyses adjusted for clinical covariates. Complementary continuous analyses were also performed. In the cabozantinib group, high levels of MET, HGF, IL-8, and ANG2 were associated with shorter OS in both univariate and multivariable dichotomized analyses (\( p < 0.05 \); Table 1). The associations of MET, IL-8, and ANG2 (but not HGF) were also observed by continuous analyses (online suppl. Table 1; see www.karger.com/doi/10.1159/000519867 for all online suppl. material), suggesting possible prognostic significance with cabozantinib. In the placebo group, high levels of MET, HGF, GAS6, IL-8, and ANG2 and low levels of IGFl-1 were associated with shorter OS in both univariate and multivariable dichotomized analyses (Table 1); these results were also observed by continuous analyses (online suppl. Table 1), suggesting possible prognostic significance with the placebo. Other biomarkers were associated with OS in univariate dichotomized and continuous analyses but not when adjusted for clinical covariates; these included AXL, GAS6, EPO, and IGFl-1 in the cabozantinib group and VEGF-A in the placebo group (Table 1; online suppl. Table 1).

The association between PFS and baseline biomarker levels was also evaluated using dichotomized and continuous analyses, both unadjusted and adjusted for clinical covariates. The only biomarker in either treatment group that was consistently associated with PFS using the 4 different approaches was ANG2 in the cabozantinib group, in which high baseline levels were associated with shorter PFS (online suppl. Tables 2, 3). High HGF in the cabozantinib group and high MET in the placebo group were associated with shorter PFS in the unadjusted and adjusted dichotomized analyses (online suppl. Table 2), but these results were not observed in the continuous analyses (online suppl. Table 3).

OS and PFS were also evaluated for cabozantinib versus placebo in subgroups defined by baseline biomarker levels dichotomized at the median. HRs favored cabozantinib over the placebo for both OS and PFS at low and high levels for all biomarkers analyzed (Fig. 1). Among all
Table 1. OS within each treatment group comparing high versus low baseline biomarker levels

| Plasma biomarker | Cabozantinib | Placebo |
|------------------|--------------|---------|
|                  | univariate   | multivariable adjusted for clinical covariates | univariate |
|                  | HR (95% CI)  | p value | HR (95% CI) | p value |
| MET              | 1.64 (1.31–2.06) | <0.001 | 1.32 (1.04–1.68) | 0.024 |
| AXL              | 1.53 (1.22–1.92) | <0.001 | 1.03 (0.80–1.33) | 0.804 |
| VEGFR2           | 0.98 (0.78–1.23) | 0.850 | 1.05 (0.84–1.33) | 0.653 |
| HGF              | 1.73 (1.38–2.18) | <0.001 | 1.37 (1.07–1.76) | 0.014 |
| GAS6             | 1.60 (1.27–2.01) | <0.001 | 1.00 (0.77–1.30) | 0.994 |
| VEGF-A           | 1.21 (0.96–1.52) | 0.107 | 1.15 (0.91–1.45) | 0.238 |
| PIGF             | 1.09 (0.86–1.38) | 0.476 | 0.88 (0.69–1.12) | 0.303 |
| IL-8             | 1.80 (1.43–2.27) | <0.001 | 1.56 (1.23–1.97) | <0.001 |
| EPO              | 1.52 (1.21–1.91) | <0.001 | 1.24 (0.98–1.57) | 0.075 |
| ANG2             | 2.05 (1.62–2.58) | <0.001 | 1.69 (1.32–2.16) | <0.001 |
| IGF-1            | 0.68 (0.54–0.85) | 0.001 | 0.88 (0.69–1.13) | 0.320 |
| VEGF-C           | 1.04 (0.83–1.31) | 0.715 | 1.28 (1.02–1.62) | 0.036 |
| c-KIT            | 0.95 (0.75–1.19) | 0.631 | 0.85 (0.68–1.08) | 0.185 |

Baseline biomarker levels were dichotomized at the median of the combined treatment groups. HRs <1 favor high over low biomarker levels. p values <0.05 are in bold. CI, confidence interval; HR, hazard ratio; OS, overall survival.

Baseline biomarkers, the lowest HR for OS was 0.65 for low AXL, and the highest HR for OS was 0.92 for high AXL; the lowest HR for PFS was 0.41 for high IGF-1, and the highest HR for PFS was 0.54 for low IGF-1.

Baseline biomarkers were evaluated for potential predictive significance by modeling the interaction between treatment and the biomarker level. No baseline biomarkers were associated with a predictive effect for OS or PFS at a significance level of 0.05 (Fig. 1). The lowest pInteraction for OS was observed for AXL; pInteraction was 0.087 in the dichotomized analysis and 0.114 in the dichotomized analysis adjusted for clinical covariates (not shown). The forest plot shows the greater relative OS treatment benefit with cabozantinib at low versus high baseline AXL levels; this benefit did not reach statistical significance.

The change in plasma levels from baseline to Week 4 was determined for 9 biomarkers (MET, AXL, VEGFR2, HGF, GAS6, VEGF-A, PIGF, IL-8, and EPO). As shown in Table 2, the largest median fold decreases with cabozantinib were observed for VEGFR2 (0.60-fold change) and HGF (0.71-fold change), and the largest median fold increases were observed for PIGF (4.28-fold change) and VEGF-A (3.80-fold change). Cabozantinib also promoted smaller increases in the levels of AXL, GAS6, and EPO from baseline that were statistically different versus changes with the placebo. Although on-treatment MET levels increased in the cabozantinib group, this change was not significant compared with the increase observed with the placebo. Small but statistically significant changes from baseline were also seen for several biomarkers in the placebo group, including increases in PIGF, VEGF-A, MET, and VEGFR2 and decreases in EPO and GAS6.

The association of on-treatment changes in biomarker levels with OS and PFS was evaluated by continuous analysis based on the log2-fold change in biomarker levels at Week 4 from baseline. Increasing VEGFR2 was associated with longer OS in the cabozantinib group in univariate analysis but not when adjusted for clinical covariates (Table 3). In the placebo group, increasing levels of MET, AXL, VEGFR2, HGF, GAS6, and IL-8 were associated with shorter OS in both univariate and multivariable analyses (Table 3), suggesting potential prognostic significance. Increasing levels of AXL and HGF were also associated with shorter PFS in the placebo group in both univariate and multivariable analyses (online suppl. Table 4).

On-treatment changes in biomarker levels at Week 4 were tested for predictive significance by modeling the interaction between treatment and the biomarker level. Increases in the plasma levels of MET, AXL, VEGFR2, HGF, GAS6, and IL-8 were associated with shorter OS in both univariate and multivariable analyses (Table 3), suggesting potential prognostic significance. Increasing levels of AXL and HGF were also associated with shorter PFS in the placebo group in both univariate and multivariable analyses (online suppl. Table 4). No plasma biomarkers were associated with a differential treatment benefit for PFS (online suppl. Table 5).
| Baseline Biomarker | Overall Survival | Progression-Free Survival |
|-------------------|----------------|--------------------------|
|                   | Patients (Cabo/Pbo) | Median, mo (Cabo/Pbo) | HR (95% CI) | p interaction | Median, mo (Cabo/Pbo) | HR (95% CI) | p interaction |
| MET Low/High      | All patients 470/237 | 10.2/8.0 | 0.76 (0.63–1.02) | NA | 5.2/1.9 | 0.44 (0.36–0.52) | NA |
| AXL Low/High      | 222/115 | 14.0/10.6 | 0.75 (0.57–1.00) | 0.991 | 5.6/2.0 | 0.45 (0.34–0.58) | 0.965 |
| VEGFR2 Low/High   | 225/112 | 8.5/5.9 | 0.79 (0.61–1.02) | 0.087 | 3.8/1.9 | 0.48 (0.37–0.61) | 0.735 |
| HGF Low/High      | 224/113 | 12.4/8.2 | 0.65 (0.49–0.86) | 0.091 | 3.8/1.9 | 0.45 (0.35–0.59) | 0.735 |
| GAS6 Low/High     | 223/114 | 9.1/7.1 | 0.92 (0.71–1.19) | 0.087 | 3.8/1.9 | 0.49 (0.38–0.63) | 0.735 |
| VEGF-A Low/High   | 232/105 | 9.7/7.2 | 0.72 (0.55–0.95) | 0.075 | 4.7/1.9 | 0.49 (0.38–0.63) | 0.705 |
| PIGF Low/High     | 215/122 | 11.1/9.2 | 0.62 (0.63–1.08) | 0.475 | 5.5/1.9 | 0.45 (0.35–0.58) | 0.705 |
| IL-8 Low/High     | 216/121 | 14.7/10.6 | 0.78 (0.59–1.04) | 0.339 | 5.6/2.0 | 0.46 (0.35–0.59) | 0.666 |
| EPO Low/High      | 231/106 | 8.1/5.5 | 0.70 (0.54–0.91) | 0.512 | 4.1/1.9 | 0.45 (0.35–0.58) | 0.761 |
| ANG2 Low/High     | 217/120 | 14.4/9.4 | 0.69 (0.52–0.93) | 0.247 | 5.5/2.1 | 0.48 (0.37–0.61) | 0.655 |
| IGF-1 Low/High    | 230/107 | 8.6/6.6 | 0.81 (0.63–1.05) | 0.914 | 4.9/1.9 | 0.49 (0.38–0.64) | 0.714 |
| VEGF-C Low/High   | 224/113 | 12.3/8.9 | 0.84 (0.65–1.09) | 0.309 | 5.4/1.9 | 0.43 (0.33–0.56) | 0.930 |
| C-KIT Low/High    | 223/114 | 8.6/6.6 | 0.71 (0.53–0.94) | 0.947 | 5.5/1.9 | 0.48 (0.37–0.62) | 0.916 |
| IL-8 Low/High     | 208/114 | 11.0/9.2 | 0.83 (0.64–1.07) | 0.894 | 5.5/1.9 | 0.48 (0.37–0.62) | 0.916 |
| EPO Low/High      | 239/113 | 9.7/6.4 | 0.70 (0.52–0.94) | 0.914 | 5.5/1.9 | 0.48 (0.37–0.62) | 0.916 |
| ANG2 Low/High     | 227/110 | 14.7/9.7 | 0.77 (0.58–1.02) | 0.947 | 5.5/1.9 | 0.48 (0.37–0.62) | 0.916 |
| IGF-1 Low/High    | 220/117 | 8.1/5.4 | 0.79 (0.61–1.02) | 0.366 | 5.6/1.9 | 0.45 (0.35–0.59) | 0.723 |
| VEGF-C Low/High   | 219/118 | 14.4/8.5 | 0.68 (0.51–1.00) | 0.902 | 3.8/1.9 | 0.47 (0.36–0.60) | 0.723 |
| C-KIT Low/High    | 228/109 | 7.9/6.6 | 0.85 (0.65–1.07) | 0.309 | 5.9/1.9 | 0.44 (0.34–0.56) | 0.723 |
| VEGF-C Low/High   | 224/113 | 14.4/11.4 | 0.80 (0.60–1.07) | 0.463 | 3.8/1.9 | 0.49 (0.38–0.64) | 0.723 |
| C-KIT Low/High    | 223/114 | 7.9/5.2 | 0.72 (0.56–0.93) | 0.429 | 4.1/1.9 | 0.54 (0.42–0.70) | 0.189 |
| IGF-1 Low/High    | 225/112 | 8.5/6.0 | 0.72 (0.56–0.94) | 0.429 | 5.6/1.9 | 0.41 (0.32–0.53) | 0.193 |
| VEGF-C Low/High   | 222/115 | 13.2/9.7 | 0.82 (0.62–1.09) | 0.428 | 5.0/1.9 | 0.42 (0.33–0.55) | 0.193 |

**Fig. 1.** Forest plots of OS and PFS for cabozantinib versus placebo by baseline biomarker levels. Baseline biomarker levels were dichotomized at the median of the combined treatment groups. $p_{interaction}$ was obtained from a separate model that included the interaction between treatment and the biomarker level. OS, overall survival; PFS, progression-free survival; CI, confidence interval; HR, hazard ratio.
Discussion

The phase 3 CELESTIAL trial evaluated the efficacy and safety of cabozantinib compared with the placebo in patients with advanced HCC previously treated with sorafenib and demonstrated significantly improved OS and PFS with cabozantinib versus placebo [9]. Consistent with the results of the primary analysis, subgroup analyses based on baseline plasma biomarker levels showed improved OS and PFS with cabozantinib versus placebo at high and low concentrations for all biomarkers analyzed. A number of baseline plasma biomarkers in the placebo group were identified as potential favorable prog-

| Table 2. Plasma biomarker levels at baseline and Week 4 |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Biomarker | Cabozantinib | Placebo | Cabozantinib FC versus placebo |
| | median level, baseline | median FC, week 4 | FC, p value | median level, baseline | median FC, week 4 | FC, p value |
| MET | 260.3 | 1.14 | <0.001 | 257.8 | 1.09 | <0.001 | 0.344 |
| AXL | 9,052 | 1.13 | <0.001 | 9,077 | 1.00 | 0.597 | <0.001 |
| VEGFR2 | 10,690 | 0.60 | <0.001 | 11,160 | 1.04 | <0.001 | <0.001 |
| HG | 239.2 | 0.71 | <0.001 | 229.1 | 0.93 | 0.100 | <0.001 |
| GAS6 | 30,360 | 1.28 | <0.001 | 29,510 | 0.93 | <0.001 | <0.001 |
| VEGF-A | 17.7 | 3.80 | <0.001 | 18.1 | 1.19 | <0.001 | <0.001 |
| PIGF | 1.2 | 4.28 | <0.001 | 1.1 | 1.60 | <0.001 | <0.001 |
| IL-8 | 20.2 | 0.98 | 0.908 | 22.2 | 1.02 | 0.109 | 0.196 |
| EPO | 23.1 | 1.10 | <0.001 | 21.4 | 0.85 | <0.001 | <0.001 |
| ANG2 | 5,174 | ND | ND | 5,228 | ND | ND | ND |
| IGF-1 | 30.1 | ND | ND | 30.4 | ND | ND | ND |
| VEGF-C | 344.4 | ND | ND | 360.5 | ND | ND | ND |
| c-KIT | 52.8 | ND | ND | 54.9 | ND | ND | ND |

p values <0.05 are in bold. CI, confidence interval; FC, fold change; HR, hazard ratio; ND, not determined. * Concentrations in pg/mL except MET, IGF-1, c-KIT (ng/mL) and EPO (mIU/mL). Baseline and Week 4 measurements were paired for each patient to calculate fold changes.

| Table 3. Continuous analysis of OS by on-treatment changes in biomarker levels |
|-----------------|-----------------|-----------------|
| Biomarker | Cabozantinib | Placebo |
| | univariate | multivariable adjusted for clinical covariates | univariate | multivariable adjusted for clinical covariates |
| | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value |
| MET | 1.24 (0.85–1.80) | 0.266 | 1.37 (0.93–2.03) | 0.115 | 3.13 (1.85–5.30) | <0.001 | 2.42 (1.42–4.13) | 0.001 |
| AXL | 0.86 (0.59–1.25) | 0.423 | 0.88 (0.60–1.30) | 0.528 | 3.38 (1.71–6.70) | <0.001 | 2.57 (1.28–5.17) | 0.008 |
| VEGFR2 | 0.76 (0.58–0.99) | 0.041 | 0.77 (0.59–1.01) | 0.060 | 2.06 (1.04–4.08) | 0.037 | 2.41 (1.14–5.12) | 0.022 |
| HG | 0.83 (0.65–1.06) | 0.135 | 0.96 (0.76–1.22) | 0.743 | 2.39 (1.76–3.25) | <0.001 | 2.77 (1.97–3.89) | <0.001 |
| GAS6 | 0.82 (0.62–1.08) | 0.153 | 1.01 (0.77–1.33) | 0.927 | 1.66 (1.11–2.50) | 0.015 | 1.84 (1.22–2.79) | 0.004 |
| VEGF-A | 1.07 (0.99–1.17) | 0.098 | 1.05 (0.97–1.15) | 0.234 | 1.06 (0.90–1.23) | 0.497 | 1.12 (0.95–1.32) | 0.187 |
| PIGF | 0.99 (0.90–1.08) | 0.798 | 0.98 (0.89–1.08) | 0.744 | 1.02 (0.88–1.19) | 0.755 | 1.00 (0.86–1.17) | 0.982 |
| IL-8 | 0.88 (0.75–1.04) | 0.134 | 0.90 (0.76–1.06) | 0.220 | 1.52 (1.22–1.90) | <0.001 | 1.47 (1.17–1.85) | 0.001 |
| EPO | 0.94 (0.79–1.12) | 0.507 | 1.02 (0.86–1.20) | 0.860 | 1.13 (0.87–1.46) | 0.373 | 1.25 (0.94–1.66) | 0.119 |

Continuous analysis of the log2-transformed fold change in biomarker levels at Week 4 from baseline. HR < 1 indicates longer OS with increased protein levels at Week 4 compared with baseline. p values <0.05 are in bold. CI, confidence interval; HR, hazard ratio; OS, overall survival.
nastic biomarkers for OS, including low baseline levels of MET, HGF, GAS6, IL-8, and ANG2 and high levels of IGF-1. Among these, low baseline levels of MET, IL-8, and ANG2 were also potentially prognostic in the cabozantinib group. Several of these prognostic factors have also been identified in previous clinical studies in patients with advanced HCC including MET [5, 6], ANG2 [3, 6], HGF [5], IGF-1 [15], and IL-8 [6, 16], providing further support for their significance. Pro-inflammatory cytokines, including IL-8, have been linked to the pathogenesis of HCC and are negatively associated with clinical outcomes [16, 17]. However, none of the baseline biomarkers were found to be predictive of a treatment benefit with cabozantinib for OS or PFS. Most previous biomarker studies in HCC also failed to identify predictive factors for treatment benefit with the exception of a broad survey of plasma proteins done for the phase 3 regorafenib trial in second-line HCC [6].

Prior studies indicate that AXL plays a role in resistance to antiangiogenic therapy, including sorafenib [18, 19]. In an integrated analysis, a small cohort of patients with HCC who were treated with sorafenib and had high baseline serum levels of soluble AXL had shorter duration of sorafenib treatment and OS versus those with low baseline levels [19]. AXL was also overexpressed in HCC cell lines and correlated with epithelial-to-mesenchymal transition and sorafenib resistance. In the current study, low baseline levels of AXL were favored over high levels for OS outcomes in both cabozantinib and placebo arms in univariate analysis, but this was not maintained in multivariable analysis.

Cabozantinib promoted an increase in the plasma levels of VEGF-A and PlGF and a decrease in the level of VEGFR2, which are well-characterized pharmacodynamic effects of VEGFR TKIs [20] that have been previously reported with cabozantinib in other tumor types [21, 22]. Pharmacodynamic changes were also observed in components of other signaling pathways inhibited by cabozantinib, including an increase in AXL and its ligand GAS6 and a decrease in HGF with cabozantinib compared with the placebo. Although MET levels also increased in the cabozantinib group, this change was not significant compared with the increase also seen in the placebo group. Cabozantinib-promoted increases in AXL and GAS6 have also been reported in a phase 2 study in metastatic castration-resistant prostate cancer [19, 21]; however, effects on MET and HGF have been less pronounced and less consistent across trials, perhaps due to differences in tumor types or time points assessed [21, 22].

Although cabozantinib promoted significant pharmacodynamic effects, on-treatment changes in plasma cytokine levels were not associated with OS or PFS with cabozantinib. Likewise, extensive investigations of other VEGF signaling inhibitors have failed to find convincing evidence for a correlation between pharmacodynamic changes in plasma cytokines and angiogenic proteins and efficacy [20, 23, 24]. Consistent with these results, preclinical studies with sunitinib in nontumor-bearing mice suggest that these pharmacodynamic changes induced by VEGFR TKIs may be a systemic response to treatment rather than a tumor-dependent response [25]. In con-

**Table 4. Continuous analysis of OS: interaction between treatment and changes in biomarker levels**

| Plasma biomarker | Unadjusted | Adjusted for clinical covariates |
|------------------|------------|---------------------------------|
|                  | HRinteraction (95% CI) | pinteraction | HRinteraction (95% CI) | pinteraction |
| MET              | 0.35 (0.18–0.67) | **0.001** | 0.49 (0.26–0.93) | **0.029** |
| AXL              | 0.24 (0.11–0.54) | <**0.001** | 0.35 (0.16–0.78) | **0.010** |
| VEGFR2           | 0.34 (0.17–0.71) | **0.004** | 0.28 (0.13–0.63) | **0.002** |
| HGF              | 0.33 (0.22–0.48) | <**0.001** | 0.32 (0.21–0.47) | <**0.001** |
| GAS6             | 0.46 (0.28–0.75) | **0.002** | 0.51 (0.31–0.82) | **0.006** |
| VEGF-A           | 1.03 (0.87–1.24) | 0.711 | 0.95 (0.79–1.14) | 0.581 |
| PIGF             | 0.99 (0.83–1.19) | 0.950 | 1.02 (0.86–1.22) | 0.807 |
| IL-8             | 0.57 (0.43–0.74) | <**0.001** | 0.60 (0.46–0.80) | <**0.001** |
| EPO              | 0.83 (0.61–1.15) | 0.262 | 0.79 (0.57–1.10) | 0.160 |

Continuous analysis of the log2-transformed fold change in biomarker levels at Week 4 from baseline using a model that includes the interaction between treatment and the biomarker level. HR <1 indicates differential treatment benefit for cabozantinib versus placebo with on-treatment increase in biomarker levels. p values <0.05 are in bold. CI, confidence interval; HR, hazard ratio; OS, overall survival.
In conclusion, low baseline levels of MET, HGF, GAS6, IL-8, and ANG2 and high levels of IGF-1 were identified as potential favorable prognostic biomarkers for OS in patients with previously treated advanced HCC. Consistent with the results of the primary analysis, cabozantinib improved OS and PFS compared with the placebo at high and low baseline concentrations for all biomarkers analyzed, and no baseline biomarkers were found to be predictive of a treatment benefit for OS or PFS. Overall, the results support the use of cabozantinib in patients with HCC previously treated with sorafenib, irrespective of plasma biomarker levels. Future studies, including the combination trial of cabozantinib and atezolizumab in first-line HCC [37], will explore both circulating and tumor biomarkers related to angiogenic signaling, inflammation, and immune-cell function.

Acknowledgments

We thank the patients, their families, the investigators, the site staff, and the trial teams; David W. Markby (Exelixis) for medical writing assistance; and Michael Raffin (Fishawack Communications) for editorial assistance, which was funded by Exelixis. T. Meyer is partly funded by the NIHR UCLH Biomedical Research Centre.

Statement of Ethics

The study (NCT01908426) was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. The Ethics Committee or institutional review board at each center approved the study protocol and amendments. All patients provided written informed consent. Full list of study locations can be found at the CELESTIAL Study Record at https://clinicaltrials.gov/ct2/show/NCT01908426.
Conflict of Interest Statement

G.K.A.-A. reports research grants from Acta Biologica, Agios, AstraZeneca, Bayer, Beigene, Berry Genomics, BMS, Casi, Celgene, Exelixis, Genentech/Roche, Halozyme, Incyte, MabVax, Puma, QED, Sillajen, and Yiviva and consulting fees from Agios, AstraZeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Debio, Eisai, Lilly, Exelixis, Flatiron, Genentech/Roche, Gilead, Helio, Incyte, Ipsen, Loxo, Merck, MINA, Polaris, QED, Redhill, Silenseed, Sillajen, Sober, Therabionics, Twoxar, Vector, and Yiviva. J.-F.B. reports personal fees from Ipsen, Bayer, Eisai, Roche, AstraZeneca, and BMS. Y.-W.C. reports payment to employer from Exelixis for statistical analysis during the conduct of the study. A.L.C. reports grant and nonfinancial support from Exelixis during the conduct of the study, including support of the parent study and funding of editorial support; honoraria and advisory/consulting fees from AstraZeneca, BMS, Exelixis, Ipsen, Bayer, and Merck; honoraria, advisory/consulting fees, and speaker bureau fees from Eisai, Novartis, and Ono Pharmaceutical; honoraria, advisory/consulting fees, and travel and accommodation expenses from Genentech/Roche and IQVIA; speaker bureau fees and travel and accommodation expenses from Bayer Yakuin; and speaker bureau fees from Amgen Taiwan; A.L.C. is an editorial board member of Liver Cancer. A.E.-K. reports personal fees and nonfinancial publication support from Exelixis during the conduct of the study; personal fees from Genentech/Roche, BMS, Eisai, and Merck; grants and personal fees from AstraZeneca; personal fees from Bayer, Gilead, QED, Agenus, ABL Bio, Pieris, Cytomx, and EMD Serono; and grants from Astex. R.K.K. reports research funding grants to institution for conduct of clinical trials from Exelixis; research funding grants to institution for conduct of clinical trials and Steering Committee membership from Agios, AstraZeneca, BMS, and Merck; research funding grants to institution for conduct of clinical trials from Bayer, Lilly, EMD Serono, Novartis, QED, and Taiho; IDMC membership and advisory board fees from Genentech/Roche; personal fees for travel support and advisory board participation from Ipsen; and advisory board fees from Gilead and Exact Sciences. H.Y.L. reports no conflicts of interest. P. McAdam reports payment to employer from Exelixis for statistical analysis during the conduct of the study. P. Merle reports advisory board fees from Roche, Bayer, Lilly, Merck, Eisai, and AstraZeneca and grants and advisory board fees from Ipsen and Genoscience. T.M. reports consultancy fees from AstraZeneca, Bayer, Eisai, Ipsen, and Roche and research grants from BTG and Bayer. J.-W.P. reports grants from Ipsen-Exelixis, Genentech/Roche, AstraZeneca, and Merck and personal fees from Ipsen-Exelixis, Genentech/Roche, Bayer, Eisai, and AstraZeneca. L.R. reports grants to institution for the CELESTIAL trial, medical writing assistance, and nonfinancial support from Exelixis during the conduct of the study; consulting/advisory role fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genentech, Hengrui, Incyte, Ipsen, IQVIA, Lilly, Merck, Nerviano Medical Sciences, Roche, Sanofi, Servier, and Zymework; honoraria/lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, and Sanofi; travel expenses from Ipsen; and research funding grants to institution from Agios, ARMO BioSciences, AstraZeneca, Beigene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, Merck, Nerviano Medical Sciences, Roche, and Zymeworks. B.-Y.R. has nothing to disclose. E.W. reports employment and stock ownership from Exelixis.

Funding Sources

This study was sponsored by Exelixis. The authors and the sponsor were responsible for data collection and analysis.

Author Contributions

L.R., R.K.K., and G.K.A.-A. contributed to study conception and design; L.R., R.K.K., T.M., B.-Y.R., P. Merle, J.-W.P., J.-F.B., H.Y.L., A.T., E.W., A.L.C., A.B.E.-K., and G.K.A.-A. contributed to data acquisition; Y.-W.C. and P. McAdam contributed to data analysis; all the authors contributed to interpretation of results; L.R. and G.K.A.-A. contributed to the original draft preparation; all the authors contributed to review, editing, and approval of the manuscript.

Data Availability Statement

All relevant data generated for the biomarker analysis are included in this article and its online supplementary material files. Further inquiries can be directed to the corresponding author.

References

1 Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017 Oct 9;7(1):12870.
2 Silva JP, Gorman RA, Berger NG, Tsai S, Christians KK, Clarke CN, et al. The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. J Surg Oncol. 2017 Dec;116(7):831–40.
3 Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 Apr 15;18(8):2290–300.
4 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: are we getting there? World J Gastroenterol. 2015 Sep 28;21(36):10336–47.
5 Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomised phase II study with tivantinib. Onco target. 2016 Nov 8;7(45):72622–33.
6 Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019 May;156(6):1731–41.
7 Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282–96.
Plasma Biomarkers for Cabozantinib versus Placebo in HCC

10 Meyer T, Kelley RK, Mangeshkar M, Cheng AL. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016 May;35(21): 2687–97.

19 Pinato DJ, Brown MW, Troulis S, Aboagy EO, Beaumont J, Zhang H, et al. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer. 2019 Mar; 120(5): 512–21.

28 Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16(9):1270–9.

32 Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, et al. Alpha-fetoprotein (AFP) kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer. 2018 Jul; 119(1):19–26.

35 Marshall SW. Power for tests of interaction: effect of raising the Type I error rate. Epidemiol Perspect Innov. 2007 Jun 19:4.

37 Kelley RK, Oliver JW, Hazra S, Benzaghou F, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Prognostic and predictive factors from the phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2020 Sep 15; 26(18):4795–804.

44 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228–47.

45 Johnson PJ, Berhane S, Kagebayashi C, Sato-Ishizawa Y, Chan SL, Chan AW, Chan AK, Jian P, Mo F, et al. Serum alpha-fetoprotein levels and clinical outcomes in the phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2020 Sep 15; 26(18):4795–804.